Combination AURKA and WEE1 inhibition exhibits efficacy in EGFR or pan-ERBB inhibitor resistant head and neck squamous cell carcinoma
{{output}}
Over 600,000 cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed globally each year. Many HNSCCs overexpress the ERBB family member EGFR, and EGFR inhibitors (EGFRis) and pan-ERBB inhibitors (ERBBis) are clinically active in treatment of local... ...
